A team of Goodwin Procter attorneys advised a group of underwriters in the recent initial public offering by Regulus Therapeutics which raised $51 million from the sale of common stock.
Goodwin represented the underwriting syndicate led by Lazard Capital Markets, Cowen and Company and BMO Capital Markets. Formed in 2007, Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.
“We are delighted to have advised the underwriters and worked with the team at Regulus to bring this transaction to the market,” said Mitchell Bloom, partner in the firm’s Business Law Department and national co-chair of Goodwin’s Life Sciences Practice. “It is a tribute to the banking team and Regulus that the parties were able to execute this transaction expeditiously against the backdrop of challenging capital markets.”